{"id":145536,"date":"2025-02-27T09:54:30","date_gmt":"2025-02-27T04:24:30","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=145536"},"modified":"2025-02-27T10:40:28","modified_gmt":"2025-02-27T05:10:28","slug":"pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/","title":{"rendered":"Pharma stock to double its revenue to \u20b913,500 Cr by FY30 to keep in your radar"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3388354062\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>This pharma stock engaged in radiopharmaceuticals, allergy immunotherapy, contract manufacturing, and drug discovery services, in focus after announcing plans to double its revenue growth from 6,703 Cr to Rs. 13,500 Cr by the financial year 2030.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3472488357\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Stock Price Movement:<\/strong><\/h2><p>With a market capitalization of Rs. 15,062.42 crores, the share of <strong><a href=\"https:\/\/portal.tradebrains.in\/stocks\/JUBLPHARMA\" target=\"_blank\" rel=\"noreferrer noopener\">Jubilant Pharmova Limited <\/a><\/strong>has reached an intraday high of Rs. 946.45 per equity share, rising nearly around 0.90 percent from its previous day\u2019s close price of Rs. 938. Since then, the stock has retreated and is currently trading at Rs. 945.65 per equity share.\u00a0<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>What Happened:<\/strong><\/h2><p>Jubilant Pharmova aims to double its revenue to Rs. 13,500 Cr by FY30, up from Rs. 6,703 Cr in FY24. The company targets an EBITDA margin expansion from 15 percent to 23-25 percent, alongside achieving a zero net debt position from the current Rs. 2,457 Cr.&nbsp;<\/p><p>Additionally, it seeks to improve its RoCE to high teens from the high single digits. This ambitious growth strategy reflects Jubilant Pharmova\u2019s commitment to financial strength, operational efficiency, and long-term value creation, positioning itself for sustainable growth in the pharmaceutical sector.<\/p><div class=\"trade-content_5\" id=\"trade-3960701844\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Partnership:<\/strong><\/h2><p>Jubilant Biosys, via its subsidiary JBIRSPL, has partnered with Pierre Fabre to acquire an 80 percent stake in Jasmin, a French R&amp;D firm. This collaboration strengthens Jubilant\u2019s presence in Europe, enhancing its focus on biologics, antibody therapies, and drug discovery services.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>New product launches:<\/strong><\/h2><p>The company aims to launch six to eight products each year across the US and international markets. It has 33 ANDAs awaiting approval in the US, with three already approved in FY25. Additionally, it is increasing exports to the US from its Roorkee facility and has begun supplying products through contract manufacturing partners.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Future Outlook:<\/strong><\/h2><p>The company intends to invest USD 50 million to expand its network to nine sites, securing long-term contracts with leading manufacturers. The radio pharmacies are set to become operational by FY28, expected to drive substantial revenue and profitability, with a projected RoCE exceeding 20 percent.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Product Pipeline:<\/strong><\/h2><p>The company boasts a robust product pipeline in both the SPECT and PET categories, targeting an addressable market of approximately USD 50 million and USD 500 million, respectively, in the medium term. Additionally, in the therapeutic segment, the company is focusing on the development of MIBG.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Recent quarter results:<\/strong><\/h2><p>Jubilant Pharmova Limited&#8217;s revenue has increased from Rs. 1,677 crore in Q3 FY24 to Rs. 1,822 crore in Q3 FY25, which has grown by 8.65 percent. The net profit has also grown by 53.03 percent from Rs. 66 crore in Q3 FY24 to Rs. 101 crore in Q3 FY25.<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written By &#8211; Nikhil Naik<\/strong><\/p><\/blockquote><p class=\"has-medium-font-size\"><strong>Disclaimer<\/strong><\/p><div class=\"trade-content-10\" id=\"trade-2156878867\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing<\/strong>.<\/p><div class=\"trade-after-content\" id=\"trade-2401901435\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>This pharma stock engaged in radiopharmaceuticals, allergy immunotherapy, contract manufacturing, and drug discovery services, in focus after announcing plans to double its revenue growth from 6,703 Cr to Rs. 13,500 Cr by the financial year 2030. Stock Price Movement: With a market capitalization of Rs. 15,062.42 crores, the share of Jubilant Pharmova Limited has reached [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":111747,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[20451,27276,20452,27277,948,936,2597],"class_list":["post-145536","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-jubilant-pharmova","tag-jubilant-pharmova-latest-news","tag-jubilant-pharmova-news","tag-jubilant-pharmova-share-price","tag-stock-market","tag-stock-market-news","tag-stocks-to-watch"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock to double its revenue to \u20b913,500 Cr by FY30 to keep in your radar - Trade Brains Features<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock to double its revenue to \u20b913,500 Cr by FY30 to keep in your radar\" \/>\n<meta property=\"og:description\" content=\"This pharma stock engaged in radiopharmaceuticals, allergy immunotherapy, contract manufacturing, and drug discovery services, in focus after announcing plans to double its revenue growth from 6,703 Cr to Rs. 13,500 Cr by the financial year 2030. Stock Price Movement: With a market capitalization of Rs. 15,062.42 crores, the share of Jubilant Pharmova Limited has reached [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-27T04:24:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-27T05:10:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/\",\"name\":\"Pharma stock to double its revenue to \u20b913,500 Cr by FY30 to keep in your radar - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"datePublished\":\"2025-02-27T04:24:30+00:00\",\"dateModified\":\"2025-02-27T05:10:28+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock to double its revenue to \u20b913,500 Cr by FY30 to keep in your radar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock to double its revenue to \u20b913,500 Cr by FY30 to keep in your radar - Trade Brains Features","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock to double its revenue to \u20b913,500 Cr by FY30 to keep in your radar","og_description":"This pharma stock engaged in radiopharmaceuticals, allergy immunotherapy, contract manufacturing, and drug discovery services, in focus after announcing plans to double its revenue growth from 6,703 Cr to Rs. 13,500 Cr by the financial year 2030. Stock Price Movement: With a market capitalization of Rs. 15,062.42 crores, the share of Jubilant Pharmova Limited has reached [&hellip;]","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2025-02-27T04:24:30+00:00","article_modified_time":"2025-02-27T05:10:28+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/","name":"Pharma stock to double its revenue to \u20b913,500 Cr by FY30 to keep in your radar - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","datePublished":"2025-02-27T04:24:30+00:00","dateModified":"2025-02-27T05:10:28+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-double-its-revenue-to-13500-cr-by-fy30-to-keep-in-your-radar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock to double its revenue to \u20b913,500 Cr by FY30 to keep in your radar"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=145536"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145536\/revisions"}],"predecessor-version":[{"id":145537,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145536\/revisions\/145537"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/111747"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=145536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=145536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=145536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}